肝动脉化疗栓塞联合血管内皮抑制素介入治疗原发性肝癌的疗效和安全性

The efficacy and safety of transcatheter arterial chemoembolization combined with Endostar for primary hepatocellar carcinoma

目的:观察肝动脉化疗栓塞联合血管内皮抑制素介入治疗原发性肝细胞癌的疗效及其安全性。方法:50例原发性肝细胞癌患者接受肝动脉化疗栓塞联合血管内皮抑制素介入治疗。观察治疗后不良反应和近期疗效,以评价治疗的安全性和有效性。结果:50例原发性肝细胞癌患者接受肝动脉化疗栓塞联合血管内皮抑制素介入治疗后,主要不良反应包括Ⅰ～Ⅱ度骨髓抑制以及谷丙转氨酶和谷草转氨酶的升高,未发生严重的治疗相关不良反应。近期疗效显示,50例患者中部分缓解3例,疾病稳定40例,疾病进展7例,疾病控制率为86.0%。结论:肝动脉化疗栓塞联合血管内皮抑制素介入治疗原发性肝细胞癌是安全而有效的。

Objective：To investigate the efficacy and safety of combined therapy of transcatheter arterial chemoembolization with Endostar for primary hepatocellular carcinoma.Methods：Fifty patients with hepatocellar carcinoma were given the combined therapy of transcatheter arterial chemoembolization with Endostar.The adverse reaction and short-term efficacy were evaluated after the combined therapy to evaluate the safety and efficacy of the combined therapy.Results：After the 50 patients with hepatocellar carcinoma received the combined therapy of transcatheter arterial chemoembolization with Endostar,the mainly observed adverse effects were Ⅰ to Ⅱ degree neutropenia and elevation in hepatic enzymes.No severe adverse effects were observed in our study.The results of short-term efficacy showed that among the 50 patients with hepatocellular carcinoma 3 had partial response（PR）,40 had stable disease（SD）,and 7 had progressive disease（PD）.Disease control rate（DCR） was 86.0%.Conclusion：Transcatheter arterial chemoembolization combined with Endostar was safe and effective in the treatment of primary hepatocellular carcinoma.